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Abstract
Background: Biomarkers have been used extensively in clinical studies to assess toxicant exposure in smokers and
non-smokers and have recently been used in the evaluation of novel tobacco products. The urinary metabolite 3-
HPMA, a metabolite of the major tobacco smoke toxicity contributor acrolein, is one example of a biomarker used
to measure exposure to tobacco smoke. A number of laboratories have developed liquid chromatography with
tandem mass spectrometry (LC-MS/MS) based methods to measure urinary 3-HPMA; however, it is unclear to what
extent the data obtained by these different laboratories are comparable.
Findings: This report describes an inter-laboratory comparison carried out to evaluate the comparability of 3-HPMA
measurement between four laboratories. A common set of spiked and authentic smoker and non-smoker urine
samples were used. Each laboratory used their in-house LC-MS/MS method and a common internal standard. A
comparison of the repeatability (’r’), reproducibility (’R’), and coefficient of variation for 3-HPMA demonstrated that
within-laboratory variation was consistently lower than between-laboratory variation. The average inter-laboratory
coefficient of variation was 7% for fortified urine samples and 16.2% for authentic urine samples. Together, this
represents an inter-laboratory variation of 12.2%.
Conclusion: The results from this first inter-laboratory comparison for the measurement of 3-HPMA in urine
demonstrate a reasonably good consensus between laboratories. However, some consistent measurement biases
were still observed between laboratories, suggesting that additional work may be required to further reduce the
inter-laboratory coefficient of variation.
Background
Cigarette smoke contains thousands of chemicals, includ-
ing toxicants, which can be categorized as either gases,
semi-volatiles (gas/vapor phase), or particles (“tar” phase)
[1]. Machine-measured cigarette yields under the ISO
testing regimen do not provide an accurate estimate of
human exposure to cigarette smoke toxicants [2]. These
limitations have led to the development of methods to
quantify biomarkers for specific toxicants in biological
fluids such as urine, saliva, and plasma [3].
The gas phase, tobacco smoke toxicant acrolein
[CAS:107-02-8] (Figure 1A) has been identified by the
World Health Organization (WHO) study group on
Tobacco Product Regulation (TobReg) as a major contri-
butor to smoke toxicity [4]. This evaluation was based on
the concentration of acrolein in smoke and its toxicity
potency factor (cancer and non-cancer), established using
various models. 3-hydroxypropylmercapturic acid (3-
HPMA) is the major urinary metabolite of acrolein (Figure
1B) [5], and it can be quantified using LC-MS based meth-
ods [3,5].
One critical element in the measurement and inter-
pretation of biomarker data (including 3-HPMA) is the
comparability in method analysis between different
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instance, a study conducted by Biber and colleagues on
a common set of urinary and plasma samples comparing
nicotine and cotinine data from eleven laboratories con-
cluded that individual values could vary significantly
between laboratories [6]. In a more recent study, Bernert
and colleagues showed that good measurement reprodu-
cibility for cotinine in a common set of samples could
be achieved between six laboratories, when a standar-
dized HPLC-UV method was used [7].
In this study we tested the reproducibility of 3-HPMA
measurement between four laboratories using their in-
house method and a common set of fortified and
authentic urine samples. Each laboratory used a com-
mon reference compound and the internal standard 3-
HPMA-
13C3-
15N.
Material and methods
Reagents and samples
S y n t h e t i c3 - H P M A( r e f e r e n c ec o m p o u n d ,F i g u r e1 B )
and 3-HPMA-
13C3-
15N (internal standard, Figure 1C)
were obtained from AptoChem (Montreal, Canada). 3-
HPMA-
13C3-
15N was ordered as a custom synthesis and
the same lot was used by each laboratory. 3-HPMA-d3
was supplied by Toronto Research Chemicals (North
York, Canada). Pooled non-smoker urine samples were
supplied fortified with 3-HPMA by RECIPE Chemicals
(Munich, Germany). Four concentrations of synthetic 3-
HPMA were used: unspiked (background ≈30-50 ng/
Figure 1 Chemical structure of acrolein (A), 3-HPMA (B), and 3-
HPMA-
13C3-
15N (C). 3-HPMA and 3-HPMA-
13C3-
15N molecular
weights are also indicated.
Table 1 Analytical method characteristics
Laboratories 1 2 3 4
Method LC-ESI-MS/MS LC-ESI-MS/MS LC-ESI-MS/MS LC-ESI-MS/MS
mode positive negative positive negative
SPE (column) Phenomenex Strata-X Isolute ENV+ Waters OASIS Waters OASIS
SPE recovery (%) 74 68 75 78
HPLC column (make) Waters Xterra MS C18 Waters HILIC-Silica Waters Acquity Phenyl Thermo BioBasic AX
HPLC column (size) 50 × 2.1 mm, 2.5 μm 150 × 2.1 mm, 3 μm 100 × 2.1 mm, 1.7 μm 50 × 3 mm, 5 μm
Quantifier ion (mass) m/z 222 - 163 m/z 220 - 89 m/z 222 - 117 m/z 220 -91
Qualifier ion (mass) m/z 222 - 117 m/z 220 - 91
precision intra-day (%) 1.1 to 5.9 1.4 to 8.6 1.1 to 1.5 1.2 to 6.5
precision inter-day (%)
a 5.1 to 5.3 3.3 to 7 1.7 to 3.9 3.3 to 7.5
accuracy (%) 93.2 to 102 83.9 to 102 97.6 to 102 96.8 to 101
LOD (ng/ml) 2.21 ND
d ND ND
d
LOQ (ng/ml) 72 55 0
f 35
f
Linearity (ng/ml) 7 to 5400 25 to 10000 50 to 5000 35 to 5000
Matrix effect (%) ND 7.4 to 17 -1.7 to 19.6 -5.5 to 6.3
aValues represent the precision range obtained for low, medium, and high concentrations at the time the methods were developed, except for Lab 1 where only
low and high concentrations were tested.
bBased on calibration standards.
cLOD was an estimate based on spiked water, water being used as the SPE solvent.
dNot determined
eLOQ was established in spiked water, water being used as SPE solvent.
fMatrices used were either diluted non-smoker urine or non-smoker urine with very low 3-HPMA background.
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Prior to distribution, the samples were quantified using
one of the participating laboratories (Lab 2) in order to
ensure the quality of the preparation. The samples were
then portioned into 5-ml-aliquots, lyophilized and
shipped to the laboratories in triplicates of each sample
(3 × 4 vials with lyophilized urine). The laboratories
were advised to reconstitute the samples with 5 ml
water.
Five authentic urine samples, covering a 3-HPMA con-
centration range which reflects typical levels in non-smo-
kers to heavy smokers, were aliquoted in triplicates and
sent to the participating laboratories (3 × 5 vials). The lyo-
philized non-smoker urine samples were supplied by
RECIPE
® (Munich, Germany), a supplier of samples used
for quality assurance testing. The smoker samples were
obtained as part of a biomarker study conducted pre-
v i o u s l yb yB A T .T h ec o r r e s p o n d i n gs t u d yp r o t o c o la n d
informed consent forms were approved by the Ethics
Committee of the Bayerische landesarztekammer Munich,
Germany (v. 18.02.2008), which contained a provision for
revisiting the samples for the purpose of biomarker
method development. The clinical study was conducted in
accordance with the World Medical Association Declara-
tion of Helsinki (World Medical Association, 2004) and
International Conference on Harmonisation (ICH) Guide-
lines for Good Clinical Practice (GCP) (International Con-
ference on Harmonization, 1996).
Analytical procedure
The samples were labelled with a code number and ran-
domized prior to distribution. 10 mg of each reference
compound and the internal standard were dispatched as
a dried powder. Samples were received in one batch by
each laboratory in September 2009, and all analyses were
completed by November 2009. A summary of the analyti-
cal methods is given in Table 1, which is based on the
performance of QC samples measured prior to the initia-
tion of the study. All four laboratories used their in-
house protocol, which included a solid phase extraction
step and analysis by LC-ESI-MS/MS. The methods were
validated according to FDA guidelines.
Statistical analysis
Basic statistical analysis was carried out with MINITAB
v15.1. Individual value plots were produced to test inter-
laboratory variation of 3-HPMA concentrations. A non-
parametric Wilcoxon paired t-test was performed to com-
pare preliminary test analyses conducted with different
internal standards. Analysis of covariance was used to
compare the analytical methods at the four laboratories
using the same internal standard (3-HPMA-
13C3-
15N).
Precision statistics, as defined in ISO 5725-2 [8], were
used as a measure of random errors, and expressed as
Table 2 All urinary 3-HPMA data in ng/ml
3-HPMA (ng/ml)
Samples Lab1 Lab2 Lab3 Lab4
1apooled NS
a urine 40.6 31.9 < LOQ
b < LOQ
b pooled NS urine 29.8 30.8 < LOQ < LOQ
c pooled NS urine 40.0 30.7 < LOQ < LOQ
2afortified NS urine 466 492 396 405
b fortified NS urine 402 470 400 403
c fortified NS urine 431 471 401 402
3afortified NS urine 1302 1340 1180 1070
b fortified NS urine 1230 1270 1160 1140
c fortified NS urine 1140 1340 1150 1090
4afortified NS urine 3624 3780 3470 3220
b fortified NS urine 3714 3820 3420 3210
c fortified NS urine 3504 3970 3370 3240
5a NS urine 39.8 48.3 < LOQ < LOQ
b NS urine 48.2 46.1 < LOQ 36.6
c NS urine 62.4 46.9 < LOQ 35.1
6a smoker urine 371 376 269 321
b smoker urine 376 382 294 269
c smoker urine 371 370 300 258
7a smoker urine 870 842 613 556
b smoker urine 960 874 673 659
c smoker urine 840 830 721 619
8a smoker urine 1080 1200 862 969
b smoker urine 1122 1160 925 914
c smoker urine 1044 1180 878 929
9a smoker urine 1482 1390 1200 1100
b smoker urine 1296 1370 1210 1130
c smoker urine 1260 1390 1100 894
Samples are numbered from 1 to 9. Samples 1 non-smoker urine, samples 2-4
= fortified samples, and samples 5-9 = authentic urine samples. Each sample
was aliquoted in triplicates labeled a, b, and c.
aNS: non smokers
b< LOQ: below limit of quantification
Figure 2 Boxplot of non-parametric differences between 3-
HPMA measured in all samples using 3-HPMA-d3 and 3-HPMA-
13C3-
15N internal standards. The hypothesis (Ho) is based on no
difference (0) between the 3-HPMA-d3 measures minus the 3-
HPMA-
13C3-
15N measures. The box plot shows a clear positive
difference with p = 0 based on a Wilcoxon paired t-test with a 95%
confidence interval for the mean difference (x).
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Page 3 of 6repeatability (’r’) and reproducibility (’R’). For the purposes
of this study, in which each laboratory used its own
method, ‘R’ refers to inter-laboratory variation.
Results and discussion
Data for both fortified and authentic urine, using 3-
HPMA-
13C3-
15N as internal standard, were reported by
each lab and the corresponding 3-HPMA concentrations
(ng/ml) are shown in Table 2. In addition, laboratory 1
repeated the measurements using two different internal
standards - 3-HPMA-d3 and 3-HPMA-
13C3-
15N-w h i c h
were prepared and analyzed on the same day, in order to
investigate the potential confounding effects of using dif-
ferent standards under the same analytical conditions. A
non-parametric paired t-test showed that the use of 3-
HPMA-d3 gave consistently higher concentrations than
3-HPMA-
13C3-
15N (Figure 2), highlighting the impor-
tance of standardizing the use of internal standards
across each laboratory throughout the study.
A background level of 40 to 60 ng/ml 3-HPMA was
observed in the non-smoker samples selected for this
study. This is expected given that acrolein is also the pro-
duct of lipid peroxidation, fossil fuel combustion, and is
found in cooked food [9].
As a quality control check, data from the fortified urine
s a m p l e s( T a b l e2 )w e r ep l o t t e dt og e n e r a t ear e g r e s s i o n
line and the corresponding equation. Using this, the
values for the urine samples (Table 2) were recalculated
based on the 3-HPMA peak area and the 3-HPMA-
13C3-
15N internal standard. The calculated concentrations
were consistent with the reported concentrations from
each lab (Additional file 1).
Individual value plots constructed using the sample
data indicate a close similarity in the measurements,
across the broad range of 3-HPMA concentrations, for
all four laboratories using 3-HPMA-
13C3-
15N( F i g u r e3 ) .
However, an analysis of covariance (ANOVA) indicated a
significant variation between laboratories still existed
(Table 3). A closer fit could be observed between lab 1
and 2, and between lab 3 and 4. The coefficients of varia-
tion, giving an estimate of the imprecision for repeated
measures at different concentration ranges, are also
reported in Table 3. The imprecision for each concentra-
tion range should be interpreted carefully since the repli-
cate measures were obtained from three aliquots from a
Figure 3 Individual value plots for 3-HPMA (blue circles) (ng/
ml). A. Value plot for the fortified samples in four laboratories. B.
Value plot for authentic urine samples in four laboratories. Missing
values were below the LOQ.
Table 3 One way ANOVA for 3-HPMA vs laboratories
(lab1, 2, 3, and 4) for each set of samples
Mean 3-HPMA
(ng/ml)
StDev CoV P value (one-way
Anova)
Sample
1
lab1 36.8 6.1 16.5 0.186
lab2 31.13 0.7 2.1
lab3 < LOQ NA NA
lab4 < LOQ NA NA
Sample
2
lab1 433 32.2 7.4 0.002
lab2 477.7 12.4 2.6
lab3 399 2.6 0.7
lab4 403.3 1.5 0.4
Sample
3
lab1 1224 81.2 6.6 0.004
lab2 1316.7 40.4 3.1
lab3 1163.3 15.3 1.3
lab4 1100 36.1 3.3
Sample
4
lab1 3614 105.4 2.9 0.000
lab2 3856.7 100.2 2.6
lab3 3420 50 1.5
lab4 3223.3 15.3 0.5
Sample
5
lab1 50.1 11.4 22.8 0.182
lab2 47.1 1.1 2.4
lab3 < LOQ NA NA
lab4 35.8 1.1 3
Sample
6
lab1 372.4 2.77 0.7 0.000
lab2 376 6 1.6
lab3 287.7 16.4 5.7
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unique sample. The fortified samples (samples 2 to 4),
were used as an internal calibration reference to calculate
accuracies (Table 4).
A comparison of the repeatability (‘r’), reproducibility
(‘R’), and coefficient of variation for 3-HPMA demon-
strated that within-laboratory variation was consistently
lower than between-laboratory variation. The average
intra-laboratory CoV was 5%, while the average inter-
laboratory CoV was 12.2% (Table 5). The average inter-
laboratory coefficient of variation was 7% for the fortified
urine samples and 16.2% for the authentic urine samples.
These results show close comparability with those
observed by Biber and colleagues, where samples spiked
with cotinine had an inter-laboratory CoV ranging from
3 to 19%, while a CoV range of 4 to 59% was reported for
authentic urine samples of smokers [10].
The overall average inter-laboratory coefficient of varia-
tion for all samples in this study was 12.2%. A CoV value
higher than 10% might indicate that there is still some
room for improvement; however, this seems to be in line
T a b l e3O n ew a yA N O V Af o r3 - H P M Avs laboratories
(lab1, 2, 3, and 4) for each set of samples (Continued)
lab4 282.7 33.6 11.9
Sample
7
lab1 890 62.4 7 0.000
lab2 848.7 22.7 2.7
lab3 669 54.1 8.1
lab4 611.3 51.9 8.5
Sample
8
lab1 1082 39 3.6 0.000
lab2 1180 20 1.7
lab3 888.3 32.7 3.7
lab4 937.3 28.4 3
Sample
9
lab1 1346 119.1 8.85 0.006
lab2 1383.3 11.5 0.8
lab3 1170 60.8 5.2
lab4 1041.3 128.5 12.3
gNA: not applicable, fewer than three data points due to at least one measure
< LOQ.
Table 4 Accuracies calculated for each laboratory based on 3-HPMA fortified samples at 400 ng/ml (samples 2), 1200
ng/ml (samples 3), and 3600 ng/ml (samples 4)
Accuracies (%)
Fortified sample (ng/ml) Lab1 Lab2 Lab3 Lab4
400 ng/ml 108 119 99 101
1200 ng/ml 102 110 97 92
3600 ng/ml 100 107 95 90
aAverage calculated over three independent measures
Table 5 Repeatability, reproducibility, and intra, inter-laboratory coefficient of variation for 3-HPMA between the four
participating laboratories
Samples Mean 3-HPMA (ng/ml)
a r
b R
c CoV within (%)
d CoV between (%)
e
1 34 5.8 13.9 6.1 NA
f
2 428 50 100.8 4.2 8.4
3 1201 142.7 261.8 4.2 7.8
4 3528 268.4 460.3 2.7 4.7
5 45 7.6 24.2 5.9 NA
f
6 330 54.9 138 6 15
7 755 143.3 363.4 6.8 17.2
8 1021 89.1 346.4 3.1 12.1
9 1235 223.1 710.1 6.5 20.5
aMean of individual 3-HPMA values for all participating laboratories and for the corresponding sample set
bReproducibility
cRepeatability
dcomposite intralaboratory coefficient of variation
einter-laboratory coefficient of variation for the four participating laboratories
fNA: not applicable due to data < LOQ
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vious studies have reported average inter-laboratory coeffi-
cients of variation (CoV) above 10% [11-13].
The results from this first inter-laboratory comparison
for the measurement of 3-HPMA in urine demonstrate a
reasonably good consensus between laboratories, with an
average CoV of 12.2%. However, some consistent mea-
surement biases were still observed between laboratories,
suggesting that additional work may be required to reduce
the inter-laboratory CoV even further.
Additional material
Additional file 1: Authentic urine 3-HPMA concentrations
recalculated using a calibration curve derived from the urine
samples spiked with synthetic 3-HPMA. The 3-HPMA fortified non-
smokers urine samples were used to establish 3-HPMA calibration curves
for each laboratory. The concentration of 3-HPMA in authentic smokers
urine was back-calculated based on the calibration curve and peak areas.
The values were compared with the values obtained by each lab with
their own calibration curve.
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